mouse monoclonal anti cd8 antibody (Nichirei Biosciences)
86
Structured Review
Nichirei Biosciences
mouse monoclonal anti cd8 antibody
Mouse Monoclonal Anti Cd8 Antibody, supplied by Nichirei Biosciences, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd8/anti+cd8/pm42286385-41-1-7
Average 86 stars, based on 1 article reviews
Mouse Monoclonal Anti Cd8 Antibody, supplied by Nichirei Biosciences, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd8/anti+cd8/pm42286385-41-1-7
Average 86 stars, based on 1 article reviews
mouse monoclonal anti cd8 antibody - by Bioz Stars,
2026-10
86/100 stars
Images
Related Articles
other:Article Title: HLA-DR and CD74 Expression and the Immune Microenvironment in Renal Cell Carcinoma. Article Snippet: Anti-HLA-A/B/C (clone EMR8-5, Hokudo, Hokkaido, Japan), antiHLA-DR (clone TAL1B5, Santa Cruz Biotech, Dallas, TX, USA), anti-CD74 (clone LN2, Santa Cruz Biotech), Article Title: Clinical Significance of Tumor Immune Microenvironment in Endometrial Endometrioid Carcinoma, Grade 1 With DNA Mismatch Repair Protein Loss Article Snippet: The administration of immune checkpoint inhibitors (ICIs) is increasing in endometrial cancer, especially in the mismatch repair (MMR)-deficient group.. To prevent unnecessary immune-related adverse events, ICIs need to be administered to more appropriate patients.. The tumor immune microenvironment has been reported to be a predictive marker of the efficacy of ICI therapies. Article Title: Prognostic and histologic significances of the expression profile of membrane tissue factor for aggressive endometrial carcinomas Article Snippet: Antibodies used were anti-TF (CD142) (mouse monoclonal, 1:50, BioMedica Diagnostics, Stamford, CT, USA), anti-p-TF (pSer 290) (rabbit polyclonal, 1:100, Sigma-Aldrich, St. Louis, MO, USA), anti-PAR-1 (ATAP2) (mouse monoclonal, 1:150, Santa Cruz, Dallas, TX, USA), anti-PAR-2 (SAM11) (mouse monoclonal, 1:100, Santa Cruz, Dallas, TX, USA), anti-VEGF (C-1) (mouse monoclonal, 1:50, Santa Cruz, Dallas, TX, USA), and Article Title: Prognostic and histologic significances of the expression profile of membrane tissue factor for aggressive endometrial carcinomas. Article Snippet: Antibodies used were anti-TF (CD142) (mouse monoclonal, 1:50, BioMedica Diagnostics, Stamford, CT, USA), antip-TF (pSer 290) (rabbit polyclonal, 1:100, Sigma-Aldrich, St. Louis, MO, USA), antiPAR-1 (ATAP2) (mouse monoclonal, 1:150, Santa Cruz, Dallas, TX, USA), anti-PAR-2 (SAM11) (mouse monoclonal, 1:100, Santa Cruz, Dallas, TX, USA), anti-VEGF (C-1) (mouse monoclonal, 1:50, Santa Cruz, Dallas, TX, USA) and |